NMC
PDSB icon

Nine Masts Capital’s PDS Biotechnology PDSB Stock Holding History

Nine Masts Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Buy
+67,507
New +$50.8K 0.01% 176

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nine Masts Capital's PDSB Position: Q1 2026 in Review

Nine Masts Capital opened a new position in PDS Biotechnology (PDSB) in Q1 2026: 67,507 shares worth $40.8K. The stake represents 0.01% of the portfolio and ranks #176 among its holdings.

41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Nine Masts Capital held 67,507 shares of PDS Biotechnology worth $40.8K as of Q1 2026.
  • PDS Biotechnology was a new Nine Masts Capital position in Q1 2026.
  • PDS Biotechnology made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #176 holding.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.